Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies

Expert Rev Hematol. 2011 Oct;4(5):483-6. doi: 10.1586/ehm.11.50.
No abstract available

Publication types

  • Review

MeSH terms

  • Boronic Acids / therapeutic use
  • Bortezomib
  • Cyclin-Dependent Kinases / antagonists & inhibitors*
  • Cyclin-Dependent Kinases / metabolism
  • Enzyme Inhibitors / therapeutic use*
  • Flavonoids / therapeutic use
  • Hematologic Neoplasms / drug therapy*
  • Hematologic Neoplasms / metabolism
  • Humans
  • NF-kappa B / metabolism
  • Piperidines / therapeutic use
  • Proteasome Endopeptidase Complex / metabolism
  • Proteasome Inhibitors*
  • Pyrazines / therapeutic use

Substances

  • Boronic Acids
  • Enzyme Inhibitors
  • Flavonoids
  • NF-kappa B
  • Piperidines
  • Proteasome Inhibitors
  • Pyrazines
  • alvocidib
  • Bortezomib
  • Cyclin-Dependent Kinases
  • Proteasome Endopeptidase Complex